Pivotal bioVenture Partners Investment Advisor LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001844645

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 13 positions · Total reported value $307.79M · Top-10 concentration 95.1% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 35.7% · 1 new · 3 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.9% · vs SPY -16.0% · Prev Value $307.79M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.7% · vs SPY -2.9% · Latest Value $245.36M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, Pivotal bioVenture Partners Investment Advisor LLC disclosed 13 equity positions with a combined reported value of $307.79M. The filing implies a focused portfolio: its ten largest positions account for 95.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were PCVX ($82.86M), ARQT ($33.18M), TRVI ($32.50M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Pivotal bioVenture Partners Investment Advisor LLC opened 1 new positions, trimmed 3 and fully exited 1, a turnover rate of 35.7% of positions. The portfolio's overlap with the prior quarter was 86% of names.

The largest new positions opened in Q2 2026 were AVLN ($31.83M).

Of the 1 positions fully exited versus the prior quarter, the largest were BOLT ($172.03K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • AVLN AVALYN PHARMACEUTICALS INC · $31.83M

Fully Exited (vs previous quarter)

  • BOLT Bolt Biotherapeutics · prev qtr: $172.03K

Insider Transactions (Form 4)

Latest Pivotal bioVenture Partners Investment Advisor LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Pivotal bioVenture Partners Investment Advisor LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 13 US equity positions with a combined value of $307.79M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 13 positions · $307.79M reported value (Q2 2026)
  • Top 10 holdings = 95.1% of reported value
  • Largest position: PCVX (VAXCYTE INC) at 26.9%
  • Average position size: $23.68M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 3 added, 3 reduced, 1 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The Pivotal bioVenture Partners Investment Advisor LLC appears to maintain a cautiously optimistic outlook on the healthcare sector, as evidenced by its active addition and reduction in holdings, with a particular focus on biotechnology and pharmaceutical companies. 2. Key Moves: - Additions: Avalyn Pharma (AVLN) was added as a new holding, suggesting a new interest in this specific company. Trevi Therapeutics (TRVI) saw a significant increase of 12.2% in share count, indicating a strong belief in the company's potential. - Reductions: Arcutis Biotherapeutics (ARQT) experienced the most substantial reduction of 6.7%, which could reflect concerns or a change in strategy regarding this company. Zenas Biopharma (ZBIO) also saw a reduction of 17.1% in share count. - No Change: The majority of holdings saw no change in share count or were held steady. 3. Portfolio Structure: - Passive vs. Active: The portfolio seems to lean towards active management, given the specific share count changes and the addition of a new holding. - Sector Bias: The fund has a clear bias towards the healthcare sector, particularly in biotechnology and pharmaceuticals. - Risk Appetite: The addition of a new holding and the significant increase in Trevi Therapeutics (TRVI) suggests a moderate to high risk appetite, as these are often considered higher-risk sectors. 4. Per-Holding One-Liner: - PCVX: VaxCyte Inc. – Biotechnology company focusing on cell therapy (unverified). - ARQT: Arcutis Biotherapeutics Inc. – Biotechnology company developing therapies for dermatological conditions (unverified). - TRVI: Trevi Therapeutics Inc. – Biotechnology company focused on rare genetic diseases (unverified). - AVLN: Avalyn Pharma Inc. – Biotechnology company specializing in orphan drug development (unverified). - EVMN: Evommune Inc. – Biotechnology company focused on developing immune modulatory drugs (unverified). - MPLT: Maplight Therapeutics Inc. – Biotechnology company developing treatments for cancer (unverified). - OCS: Oculis Holding AG – Biotechnology company focused on ophthalmology (unverified). - BIOA: Bioage Labs Inc. – Biotechnology company focused on longevity and age-related diseases (unverified). - IMNM: Immunome Inc. – Biotechnology company working on cancer immunotherapies (unverified). - ZBIO: Zenas Biopharma Inc. – Biotechnology company focusing on drug discovery and development (unverified). 5. One-Sentence Style Summary: Pivotal bioVenture Partners demonstrates a strategic shift in its healthcare investments, emphasizing biotechnology with a focus on high-potential companies while reducing exposure to some established players.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.43M $82.86M 26.92%
26.92%
Add
2 1.27M $33.18M 10.78%
10.78%
Reduce
3 1.74M $32.50M 10.56%
10.56%
Add
4 966.79K $31.83M 10.34%
10.34%
New
5 1.93M $25.61M 8.32%
8.32%
Hold
6 611.45K $21.91M 7.12%
7.12%
Hold
7 1.51M $20.89M 6.79%
6.79%
Reduce
8 653.37K $16.01M 5.20%
5.20%
Hold
9 732.51K $15.52M 5.04%
5.04%
Hold
10 490.77K $12.46M 4.05%
4.05%
Reduce
11 434.03K $8.02M 2.61%
2.61%
Add
12 300.58K $4.81M 1.56%
1.56%
Hold
13 595.52K $2.19M 0.71%
0.71%
Hold

FAQ

What did Pivotal bioVenture Partners Investment Advisor LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Pivotal bioVenture Partners Investment Advisor LLC reported 13 equity positions worth $307.79M in aggregate; its largest disclosed positions were PCVX ($82.86M), ARQT ($33.18M), TRVI ($32.50M).

How large is Pivotal bioVenture Partners Investment Advisor LLC's portfolio?

Pivotal bioVenture Partners Investment Advisor LLC reported $307.79M of long equity holdings across 13 positions as of 2026-Q2. Top-10 holdings account for 95.1% of reported value.

What is Pivotal bioVenture Partners Investment Advisor LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/pivotal-bioventure-partners-investment-advisor/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →